Inicio・Lista de Acciones・Cytokinetics Inc

Cytokinetics Inc

Cerrado

SectorSanidad

76.02 -1.43

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

74.77

Máximo

77.12

Métricas clave
By Trading Economics
Ingresos	-23M -206M
Ventas	1.6M 19M
BPA	-1.67
Margen de beneficios	-1,064.485
Empleados	673
EBITDA	11M -169M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+42.36% upside

Dividendos
By Acuity
Próximas Ganancias	6 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	2.7B 11B
Apertura anterior	77.45
Cierre anterior	76.02

Cytokinetics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

3 ago 2026, 19:36 UTC

Cytokinetics Inc shares are lower amid broader market trends influenced by geopolitical developments. Earlier in the session, shares pulled back from a session high.

31 jul 2026, 20:02 UTC

Event

Cytokinetics Inc is lower today amid a broader decline in the Biotechnology sub-sector, reversing a trend of higher daily closes since Thursday.

30 jul 2026, 18:46 UTC

Event

News

Social Media

Cytokinetics receives UK marketing authorization for MYQORZO, a treatment for obstructive hypertrophic cardiomyopathy. Shares are trading higher amid positive market sentiment.

29 jul 2026, 20:41 UTC

Cytokinetics Inc shares are lower in after-market hours, influenced by a broader market decline amid rising crude oil prices and anticipation of the Fed's policy announcement.

28 jul 2026, 19:06 UTC

News

Cytokinetics shares are lower amid investor concerns over CEO Robert I. Blum's recent stock option exercise and sale, reported earlier today.

27 jul 2026, 19:56 UTC

Social Media

Cytokinetics Inc shares are lower, continuing a recent decline, amid social media discussions of a $103 price target and anticipated Myqorzo earnings in 2026.

24 jul 2026, 23:46 UTC

Cytokinetics Inc shares are lower in after-market hours, continuing recent weakness after three consecutive daily declines. No specific news was identified for the move.

22 jul 2026, 23:16 UTC

Cytokinetics Inc shares are lower in after-market hours amid broader market weakness, with no specific news identified to explain the decline.

21 jul 2026, 18:16 UTC

Cytokinetics Inc is trading higher, with no specific news identified. The stock has gained since Monday amid rising commodity prices, particularly copper and oil.

20 jul 2026, 19:22 UTC

News

Social Media

Cytokinetics shares are lower amid declines in the Biotechnology sector. Myqorzo revenue expectations exceed consensus, with a long-term projection of $1.67 billion by 2030.

Comparación entre iguales

Cambio de precio

Cytokinetics Inc previsión

Precio Objetivo

By TipRanks

42.36% repunte

Estimación a 12 Meses

Media 109.8 USD 42.36%

Máximo 146 USD

Mínimo 83 USD

De acuerdo con 16 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Cytokinetics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

16 ratings

Comprar

Mantener

Vender

De acuerdo con 16 analistas que ofrecen calificaciones bursátiles a para Cytokinetics Inc Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.